Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
NHC vs UNH vs CVS vs HCSG vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Care Facilities
Medical - Distribution
NHC vs UNH vs CVS vs HCSG vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Care Facilities | Medical - Distribution |
| Market Cap | $2.66B | $335.60B | $111.40B | $1.60B | $92.15B |
| Revenue (TTM) | $1.50B | $449.71B | $407.90B | $1.84B | $403.43B |
| Net Income (TTM) | $101M | $12.04B | $2.93B | $59M | $4.76B |
| Gross Margin | 38.5% | 18.8% | 13.9% | 13.3% | 3.6% |
| Operating Margin | 8.1% | 4.2% | 1.5% | 3.0% | 1.5% |
| Forward P/E | 21.5x | 20.2x | 12.2x | 20.8x | 19.3x |
| Total Debt | $87M | $78.39B | $93.59B | $25M | $7.39B |
| Cash & Equiv. | — | $24.36B | $8.51B | $161M | $5.69B |
NHC vs UNH vs CVS vs HCSG vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| National HealthCare… (NHC) | 100 | 255.6 | +155.6% |
| UnitedHealth Group … (UNH) | 100 | 121.3 | +21.3% |
| CVS Health Corporat… (CVS) | 100 | 133.2 | +33.2% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| McKesson Corporation (MCK) | 100 | 474.1 | +374.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NHC vs UNH vs CVS vs HCSG vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
NHC has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 13.2%, EPS growth 17.5%, 3Y rev CAGR 11.0%
- 6.7% margin vs CVS's 0.7%
- +81.9% vs UNH's -3.2%
UNH ranks third and is worth considering specifically for income & stability.
- Dividend streak 25 yrs, beta 0.59, yield 2.4%
- 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend)
CVS is the clearest fit if your priority is defensive.
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.2x vs 20.2x)
HCSG is the clearest fit if your priority is efficiency.
- 7.3% ROA vs CVS's 1.1%, ROIC 9.0% vs 5.0%
MCK is the #2 pick in this set and the best alternative if long-term compounding and sleep-well-at-night is your priority.
- 348.1% 10Y total return vs NHC's 198.2%
- Lower volatility, beta 0.04, current ratio 0.90x
- PEG 0.49 vs NHC's 0.93
- 16.2% revenue growth vs HCSG's 7.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs HCSG's 7.1% | |
| Value | Lower P/E (12.2x vs 20.2x) | |
| Quality / Margins | 6.7% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.04 vs HCSG's 1.12 | |
| Dividends | 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +81.9% vs UNH's -3.2% | |
| Efficiency (ROA) | 7.3% ROA vs CVS's 1.1%, ROIC 9.0% vs 5.0% |
NHC vs UNH vs CVS vs HCSG vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
NHC vs UNH vs CVS vs HCSG vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
NHC leads in 2 of 6 categories
CVS leads 1 • HCSG leads 1 • UNH leads 0 • MCK leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
NHC leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 299.7x NHC's $1.5B. NHC is the more profitable business, keeping 6.7% of every revenue dollar as net income compared to CVS's 0.7%. On growth, NHC holds the edge at +12.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.5B | $449.7B | $407.9B | $1.8B | $403.4B |
| EBITDAEarnings before interest/tax | $166M | $23.2B | $10.5B | $72M | $6.8B |
| Net IncomeAfter-tax profit | $101M | $12.0B | $2.9B | $59M | $4.8B |
| Free Cash FlowCash after capex | $147M | $19.7B | $7.4B | $139M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +38.5% | +18.8% | +13.9% | +13.3% | +3.6% |
| Operating MarginEBIT ÷ Revenue | +8.1% | +4.2% | +1.5% | +3.0% | +1.5% |
| Net MarginNet income ÷ Revenue | +6.7% | +2.7% | +0.7% | +3.2% | +1.2% |
| FCF MarginFCF ÷ Revenue | +9.8% | +4.4% | +1.8% | +7.6% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +12.5% | +2.0% | +6.2% | +6.6% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -8.4% | +0.7% | +63.1% | +175.0% | +37.0% |
Valuation Metrics
CVS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 22.3x trailing earnings, NHC trades at a 64% valuation discount to CVS's 62.8x P/E. Adjusting for growth (PEG ratio), MCK offers better value at 0.75x vs NHC's 0.97x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.7B | $335.6B | $111.4B | $1.6B | $92.1B |
| Enterprise ValueMkt cap + debt − cash | $2.7B | $389.6B | $196.5B | $1.5B | $93.8B |
| Trailing P/EPrice ÷ TTM EPS | 22.35x | 27.95x | 62.81x | 27.54x | 29.25x |
| Forward P/EPrice ÷ next-FY EPS est. | 21.51x | 20.19x | 12.19x | 20.83x | 19.28x |
| PEG RatioP/E ÷ EPS growth rate | 0.97x | — | — | — | 0.75x |
| EV / EBITDAEnterprise value multiple | 15.85x | 16.70x | 13.11x | 22.38x | 18.74x |
| Price / SalesMarket cap ÷ Revenue | 1.81x | 0.75x | 0.28x | 0.87x | 0.26x |
| Price / BookPrice ÷ Book value/share | 2.50x | 3.31x | 1.47x | 3.19x | — |
| Price / FCFMarket cap ÷ FCF | 17.89x | 20.88x | 14.27x | 11.49x | 17.63x |
Profitability & Efficiency
HCSG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $4 for CVS. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), HCSG scores 7/9 vs NHC's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.6% | +11.5% | +3.9% | +11.8% | +3.0% |
| ROA (TTM)Return on assets | +6.4% | +3.9% | +1.1% | +7.3% | +5.7% |
| ROICReturn on invested capital | +8.4% | +9.2% | +5.0% | +9.0% | +5.4% |
| ROCEReturn on capital employed | — | +9.7% | +6.1% | +7.7% | +30.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 5 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.08x | 0.77x | 1.24x | 0.05x | — |
| Net DebtTotal debt minus cash | $87M | $54.0B | $85.1B | -$136M | $1.7B |
| Cash & Equiv.Liquid assets | — | $24.4B | $8.5B | $161M | $5.7B |
| Total DebtShort + long-term debt | $87M | $78.4B | $93.6B | $25M | $7.4B |
| Interest CoverageEBIT ÷ Interest expense | 24.41x | 4.71x | 2.11x | 33.02x | 33.79x |
Total Returns (Dividends Reinvested)
NHC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $7,888 for HCSG. Over the past 12 months, NHC leads with a +81.9% total return vs UNH's -3.2%. The 3-year compound annual growth rate (CAGR) favors NHC at 46.5% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +31.9% | +10.6% | +10.6% | +28.6% | -8.5% |
| 1-Year ReturnPast 12 months | +81.9% | -3.2% | +34.7% | +55.8% | +4.6% |
| 3-Year ReturnCumulative with dividends | +214.6% | -19.9% | +36.6% | +48.6% | +106.4% |
| 5-Year ReturnCumulative with dividends | +162.1% | -2.6% | +17.0% | -21.1% | +286.9% |
| 10-Year ReturnCumulative with dividends | +198.2% | +220.6% | +3.5% | -26.8% | +348.1% |
| CAGR (3Y)Annualised 3-year return | +46.5% | -7.1% | +11.0% | +14.1% | +27.3% |
Risk & Volatility
Evenly matched — CVS and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a 0.04 beta — it tends to amplify market swings less than HCSG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.60x | 0.59x | 0.05x | 1.12x | 0.04x |
| 52-Week HighHighest price in past year | $184.08 | $395.52 | $88.63 | $24.39 | $999.00 |
| 52-Week LowLowest price in past year | $93.54 | $234.60 | $58.35 | $12.66 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +93.1% | +93.5% | +98.5% | +91.5% | +75.3% |
| RSI (14)Momentum oscillator 0–100 | 51.2 | 75.9 | 69.3 | 61.8 | 16.2 |
| Avg Volume (50D)Average daily shares traded | 117K | 7.9M | 7.4M | 676K | 757K |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: UNH as "Buy", CVS as "Buy", HCSG as "Hold", MCK as "Buy". Consensus price targets imply 33.8% upside for MCK (target: $1007) vs 4.2% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.06% vs MCK's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $385.43 | $95.20 | $24.50 | $1006.50 |
| # AnalystsCovering analysts | — | 52 | 41 | 15 | 31 |
| Dividend YieldAnnual dividend ÷ price | +1.4% | +2.4% | +3.1% | — | +0.4% |
| Dividend StreakConsecutive years of raises | 12 | 25 | 0 | 20 | 17 |
| Dividend / ShareAnnual DPS | $2.47 | $8.70 | $2.67 | — | $2.69 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +1.7% | 0.0% | +3.9% | +3.4% |
NHC leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CVS leads in 1 (Valuation Metrics). 2 tied.
NHC vs UNH vs CVS vs HCSG vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NHC or UNH or CVS or HCSG or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus 7. 1% for Healthcare Services Group, Inc. (HCSG). National HealthCare Corporation (NHC) offers the better valuation at 22. 3x trailing P/E (21. 5x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NHC or UNH or CVS or HCSG or MCK?
On trailing P/E, National HealthCare Corporation (NHC) is the cheapest at 22.
3x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus National HealthCare Corporation's 0. 93x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — NHC or UNH or CVS or HCSG or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.
9%, compared to -21. 1% for Healthcare Services Group, Inc. (HCSG). Over 10 years, the gap is even starker: MCK returned +348. 1% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NHC or UNH or CVS or HCSG or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.
04β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 2507% more volatile than MCK relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — NHC or UNH or CVS or HCSG or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus 7. 1% for Healthcare Services Group, Inc. (HCSG). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NHC or UNH or CVS or HCSG or MCK?
National HealthCare Corporation (NHC) is the more profitable company, earning 8.
2% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NHC leads at 8. 7% versus 1. 2% for MCK. At the gross margin level — before operating expenses — NHC leads at 37. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NHC or UNH or CVS or HCSG or MCK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus National HealthCare Corporation's 0. 93x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CVS Health Corporation (CVS) trades at 12. 2x forward P/E versus 21. 5x for National HealthCare Corporation — 9. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 33. 8% to $1006. 50.
08Which pays a better dividend — NHC or UNH or CVS or HCSG or MCK?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), NHC (1. 4% yield), MCK (0. 4% yield) pay a dividend. HCSG does not pay a meaningful dividend and should not be held primarily for income.
09Is NHC or UNH or CVS or HCSG or MCK better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, HCSG: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NHC and UNH and CVS and HCSG and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NHC is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; HCSG is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock. NHC, UNH, CVS pay a dividend while HCSG, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.